ANI Pharmaceuticals Inc

BSFA

Company Profile

  • Business description

    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    897

Stocks News & Analysis

stocks

Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing

North America was a notable blemish, down 2% on an organic basis.
stocks

Our view on Santos after production is ramped up

Barossa at 75% capacity and Pikka undergoing commissioning.
stocks

GE Aerospace earnings: No good deed goes unpunished

We’ve raised our fair value estimate of GE Aerospace stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,189.9015.700.17%
CAC 408,143.055.84-0.07%
DAX 4024,900.7144.240.18%
Dow JONES (US)49,098.71285.30-0.58%
FTSE 10010,143.446.61-0.07%
HKSE26,749.51119.550.45%
NASDAQ23,501.2465.220.28%
Nikkei 22553,846.87157.980.29%
NZX 50 Index13,448.24108.63-0.80%
S&P 5006,915.612.260.03%
S&P/ASX 2008,860.1015.000.17%
SSE Composite Index4,136.1613.590.33%

Market Movers